Welcome to our dedicated page for RLFTD news (Ticker: RLFTD), a resource for investors and traders seeking the latest updates and insights on RLFTD stock.
Relief Therapeutics Holding SA (RLFTD) is a biopharmaceutical innovator developing therapies for rare metabolic, dermatological, and respiratory conditions. This page aggregates official announcements and verified updates about the company's clinical programs, financial performance, and strategic initiatives.
Investors and industry observers will find timely updates on regulatory milestones, partnership agreements, and pipeline developments. Our curated collection includes earnings reports, intellectual property updates, and distribution network expansions directly from corporate sources.
Key focus areas include progress reports on proprietary drug delivery platforms, licensing deals for specialty therapies, and operational updates impacting treatment accessibility. All content maintains strict adherence to factual reporting standards without editorial commentary.
Bookmark this page for centralized access to Relief Therapeutics' latest verified communications. Check regularly for updates on advancements in rare disease therapeutics and corporate developments.
Relief Therapeutics Holding SA has announced an increase in its share capital from 4.62 billion to 5.62 billion shares by issuing 1 billion new shares, fully subscribed by its subsidiary, Relief Therapeutics International SA. These new shares will be listed on the SIX Swiss Exchange around December 22, 2022. Following this issuance, Relief expects about 1.2 billion shares to be held in treasury for future financing transactions, while the outstanding shares will remain unchanged until placement.
Relief Therapeutics announces leadership changes with Jack Weinstein appointed as CEO and Jeremy Meinen as CFO. Effective immediately, Weinstein aims to enhance the company's long-term strategy following the launch of their first product, PKU GOLIKE. Meinen, who has been with Relief since 2020, now takes on more responsibility in driving financial growth. These appointments come after the settlement of litigation with NRx Pharmaceuticals, signaling a strategic shift for Relief to focus on expanding its operations in the biopharmaceutical sector.
Relief Therapeutics announced the filing of Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. SEC for a proposed offering of ordinary shares in the form of American Depositary Shares (ADSs). Details regarding the number and pricing of the ADSs are yet to be determined. The company plans to list these ADSs on the NASDAQ under the symbol RLFT. The offering will only proceed with an effective prospectus.
FAQ
What is the market cap of RLFTD (RLFTD)?
